Panacea Biotec
Innovation in support of life

August 13, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 531349

Sub: (1) Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter ended June 30, 2026

(2) (i) Date, time & venue of 42nd AGM - Tuesday, September 29, 2026 at 11:30 A.M.;
(ii) Appointment of Scrutinizer for e-Voting process at AGM; and
(ii) Dates of Book Closure – September 25 – 29, 2026

Ref: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In continuation to our letter dated August 08, 2026, and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that:

1. The Board of Directors has at its meeting held today, i.e. August 13, 2026, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended June 30, 2026. The same was also reviewed by the Audit Committee in its meeting held on August 13, 2026. A copy of the said results along with the Limited Review Report is enclosed as **Annexure - A**.

   Pursuant to Regulation 46(2)(l) of the SEBI LODR Regulations, the aforesaid statements of financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com.

   Further, pursuant to Regulation 47(1)(b) of the SEBI LODR Regulations, the Quick Response Code along with the details of the webpage where complete financial results of the Company for the quarter ended June 30, 2026, are accessible to the Investors, is being sent for publication in newspapers.

2. The Board of Directors has also decided / approved:

   i) that the 42nd Annual General Meeting of the Members of the Company will be held on Tuesday, September 29, 2026, at 11:30 A.M. through Video Conferencing / Other Audio-Visual Means and approved draft Notice convening Annual General Meeting;

ANKIT JAIN
Digitally signed by ANKIT JAIN
Date: 2026.08.13 18:42:04 +05'30'

Panacea Biotec
Innovation in support of life

ii) that the Register of Members and Share Transfer Books will remain closed from Friday, September 25, 2026, to Tuesday, September 29, 2026 (both days inclusive) for the purpose of Annual General Meeting; and

iii) the appointment of Mr. Debabrata Deb Nath, Partner of R&D Company Secretaries, to act as Scrutinizer for e-Voting process on behalf of the Company for the purpose of ensuing Annual General Meeting.

The meeting of the Board of Directors commenced at 04:46 P.M. and concluded at 05:27 P.M.

This is for your information and records please.

Thanking you
Sincerely yours,
for **Panacea Biotec Limited**

ANKIT JAIN
Digitally signed by ANKIT JAIN
Date: 2026.08.13 18:42:28 +05'30'

Ankit Jain
General Manager - Legal and Company Secretary

Encl. As Above

Panacea Biotec
Innovation in support of life

Extract of Standalone and Consolidated Financial Results (Unaudited)
for the Quarter ended June 30, 2026

(₹ in Lakh except per share)

Particulars	Standalone				Consolidated			
	Quarter ended			Year ended	Quarter ended			Year ended
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
	(Unaudited)	(Audited) (Refer note 4)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer note 4)	(Unaudited)	(Audited)
Total income from operations	13,471	11,112	11,225	41,349	19,957	16,675	16,670	63,977
Net Profit / (Loss) for the period/year (before tax, exceptional and/or extraordinary item)	200	(461)	(884)	(4,385)	83	(396)	(476)	(2,687)
Net Profit / (Loss) for the period/year before tax (after exceptional and/or extraordinary item)	200	(461)	(884)	(4,385)	357	(125)	656	(737)
Net Profit / (Loss) for the period/year after tax (after exceptional and/or extraordinary item)	139	(18)	(670)	(2,988)	220	(100)	396	(716)
Total comprehensive income / (loss) for the period / year (comprising of profit / (loss) for the period / year (after tax) and other comprehensive income (after tax))	167	59	(668)	(2,874)	258	399	394	(174)
Equity Share Capital (face value of ₹1 per share)	613	613	613	613	613	613	613	613
Earning / (loss) per equity share, (annualised, except for quarters): Basic and Diluted (in ₹)	0.23	(0.03)	(1.09)	(4.88)	0.38	0.08	0.66	(0.88)

Notes:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchanges websites, NSE- https://www.nseindia.com, BSE- https://www.bseindia.com and is also available on the Company's website, https://www.panaceabiotec.com.

2 The financial results for the Quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026, and have been reviewed by the statutory auditor of the Company.

3 The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("Ind-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

4 Amounts for the Quarter Ended March 31, 2026 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only to limited review

5 Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/ year.

For and on behalf of the Board of Directors of
Panacea Biotec Limited

Place: New Delhi
Date: August 13, 2026

Panacea Biotec Ltd. New Delhi-110044

Dr. Rajesh Jain
Chairman & Managing Director

Panacea Biotec Limited
Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab
CIN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070,
Website: https://www.panacea-biotec.com, E-mail: Corporate@panaceabiotec.com

Panacea Biotec
Innovation in support of life

Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter ended June 30, 2026

(₹ in Lakh except per share)

S.No	Particulars	Standalone				Consolidated			
		Quarter ended			Year ended	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited) (Refer note 6)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer note 6)	(Unaudited)	(Audited)
I	**Income:**								
	a) Revenue from operations	13,471	11,112	11,225	41,349	19,957	16,675	16,670	63,977
	b) Other income	606	560	495	1,800	424	255	567	1,690
	Total Income	**14,077**	**11,672**	**11,720**	**43,149**	**20,381**	**16,930**	**17,237**	**65,667**
II	**Expenditure:**								
	a) Cost of raw and packing materials consumed	5,379	5,879	6,094	21,949	7,417	8,078	7,271	29,024
	b) Purchase of traded goods	20	1	114	401	77	267	201	897
	c) Changes in inventories of finished goods, traded goods and work-in-progress	2,401	(299)	6	(1,242)	2,677	(706)	250	(1,873)
	d) Employee benefits expense	2,283	2,276	2,537	10,033	4,416	4,682	4,572	18,078
	e) Finance cost	689	633	600	2,530	118	120	86	605
	f) Depreciation and amortisation expense	447	418	477	1,875	790	788	839	3,306
	g) Other expenses	2,658	3,225	2,776	11,988	4,803	4,097	4,494	18,317
	Total expenses	**13,877**	**12,133**	**12,604**	**47,534**	**20,298**	**17,326**	**17,713**	**68,354**
III	**Profit / (loss) before tax and exceptional item (I-II)**	**200**	**(461)**	**(884)**	**(4,385)**	**83**	**(396)**	**(476)**	**(2,687)**
IV	Exceptional items (refer note 5)	-	-	-	-	274	271	1,132	1,950
V	**Profit / (loss) before tax (III+IV)**	**200**	**(461)**	**(884)**	**(4,385)**	**357**	**(125)**	**656**	**(737)**
VI	**Tax expense:**								
	a) Current tax (net)	-	(159)	-	(159)	39	35	-	43
	b) Deferred tax charge / (benefit)	61	(284)	(214)	(1,238)	98	(60)	260	(64)
	Total tax expenses	**61**	**(443)**	**(214)**	**(1,397)**	**137**	**(25)**	**260**	**(21)**
VII	**Net Profit/(loss) after tax for the period/year (V-VI)**	**139**	**(18)**	**(670)**	**(2,988)**	**220**	**(100)**	**396**	**(716)**
VIII	**Profit/(loss) for the period / year attributable to:**								
	i) Owners of the Company	139	(18)	(670)	(2,988)	230	52	405	(537)
	ii) Non-controlling interest	-	-	-	-	(10)	(152)	(9)	(179)
IX	**Other comprehensive income / (loss):**								
a)	i) Items that will not be reclassified to profit or loss	38	104	2	153	51	146	(3)	203
	ii) Income tax related to above	(10)	(27)	-	(39)	(13)	(37)	1	(51)
b)	i) Items that will be reclassified to profit or loss	-	-	-	-	-	390	-	390
	ii) Income tax related to above	-	-	-	-	-	-	-	-
X	**Total comprehensive income / (loss) for the period/year (VII+IX)**	**167**	**59**	**(668)**	**(2,874)**	**258**	**399**	**394**	**(174)**
XI	**Total comprehensive income / (loss) attributable to:**								
	i) Owners of the Company	167	59	(668)	(2,874)	268	551	403	5
	ii) Non-controlling interest	-	-	-	-	(10)	(152)	(9)	(179)
XII	Paid-up equity share capital (face value of ₹1/- each)	613	613	613	613	613	613	613	613
XIII	Other equity	-	-	-	27,911	-	-	-	82,871
XIV	**Earning / (loss) per equity share (annualised, except for quarters)**								
	Basic and Diluted (in ₹)	0.23	(0.03)	(1.09)	(4.88)	0.38	0.08	0.66	(0.88)

Panacea Biotec Ltd. New Delhi-110044

Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter ended June 30, 2026				
Unaudited Segment-wise Revenue, Results and Capital Employed				
Particulars	**Consolidated**			
	Quarter ended			**Year Ended**
	June 30, 2026	**March 31, 2026**	**June 30, 2025**	**March 31, 2026**
	(Unaudited)	(Audited) (Refer note 6)	(Unaudited)	(Audited)
a) Segment revenue				
(i) Vaccines	13,467	10,795	11,225	41,025
(ii) Formulations	6,490	5,880	5,445	22,952
Sub total	**19,957**	**16,675**	**16,670**	**63,977**
Less: Inter segment revenue	-	-	-	-
Total segment revenue	**19,957**	**16,675**	**16,670**	**63,977**
b) Segment results				
Profit (+) / loss (-) before tax				
(i) Vaccines	747	(345)	(425)	(2,684)
(ii) Formulations	(390)	220	1,081	1,947
Sub total	**357**	**(125)**	**656**	**(737)**
Other unallocated expenditure net of unallocated income and exceptional items	-	-	-	-
Total Profit / (loss) before tax	**357**	**(125)**	**656**	**(737)**
c) Capital employed				
Segment assets				
(i) Vaccines	91,203	87,014	87,506	87,014
(ii) Formulations	38,245	39,203	40,151	39,203
Sub Total	**1,29,448**	**1,26,217**	**1,27,657**	**1,26,217**
Segment liabilities				
(i) Vaccines	33,164	30,202	31,321	30,202
(ii) Formulations	13,151	13,127	12,672	13,127
Sub Total	**46,315**	**43,329**	**43,993**	**43,329**
Capital employed (Segment assets - segment liabilities)				
(i) Vaccines	58,039	56,812	56,185	56,812
(ii) Formulations	25,094	26,076	27,479	26,076
Total capital employed	**83,133**	**82,888**	**83,664**	**82,888**

Panacea Biotec Ltd. New Delhi-110044

Panacea Biotec
Innovation in support of life

Notes:

1. The financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 13, 2026, and have been reviewed by the statutory auditor of the Company.

2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013.

3. The consolidated financial results of the Company have been prepared by consolidating the unaudited financial results of the Company and its material subsidiary Panacea Biotec Pharma Limited ("PBPL") for the respective periods, with the unaudited (management reviewed and approved) financial results of its wholly owned subsidiaries ("WOS") and the enterprises over which the Company exercises control ("Enterprises") (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as "the Group") for the respective periods:
   (i) WOS: Meyten Realtech Private Limited, Panacea Biotec (International) S.A. ("PBS"), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and
   (ii) Enterprises*: PanEra Biotec Private Limited and Adveta Power Private Limited.
   **considered as a subsidiary for the purpose of consolidation as per Ind AS 110*

4. For the quarter ended June 30, 2026, the Company and Group has earned profit (including other comprehensive income) of ₹167 lakh and ₹258 lakh (quarter ended June 30, 2025: loss of ₹668 lakh and profit of ₹394 lakh), respectively. As on June 30, 2026, the retained earnings of the Company are negative to the extent of ₹21,615 lakh (June 30, 2025: ₹19,577 lakh). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group as on June 30, 2026 are positive. The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers, resulting into higher revenues and profits during the current quarter. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis.

5. During the quarter ended June 30, 2026, the Group has recognised exceptional income of ₹274 lakh (quarter ended June 30, 2025: ₹1,132 lakh) in the consolidated statement of profit and loss, which includes:
   (i) income of ₹ Nil (quarter ended June 30, 2025: ₹858 lakh), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA ("Apotex") to settle the ongoing dispute between Apotex and the Company & PBPL; and
   (ii) income of ₹274 Lakh (quarter ended June 30, 2025: ₹274 lakh), out of the remaining deferred consideration of ₹1,019 Lakh as at March 31, 2026, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of ₹745 lakh (June 30, 2025: ₹1,837 lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group.

6. Amounts for the quarter ended March 31, 2026 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the financial year ended March 31, 2026, which had been subjected only to limited review.

Panacea Biotec Ltd. New Delhi-110044

Panacea Biotec
Innovation in support of life

7. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, 'Operating Segments', the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter ended June 30, 2026.

8. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors.

9. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year.

10. '0' under "₹ in Lakh" represents an amount less than ₹50,000. Further, the figures shown in the tables may not exactly add up due to rounding off.

11. The above results are also available on the Company's website https://www.panaceabiotec.com.

For and on behalf of the Board of Directors of
Panacea Biotec Limited

Place: New Delhi
Date: August 13, 2026

Dr. Rajesh Jain
Chairman and Managing Director

Panacea Biotec Ltd. New Delhi-110044

Suresh Surana & Associates LLP
Chartered Accountants

Suresh Surana & Associates LLP
2nd Floor, Tower-B
B-37 Sector-1
Noida (NCR) - 201301, (U.P), India
T +91 (120) 626 5555
newdelhi@ss-associates.com www.ss-associates.com
LLP Identity No. AAB-7509

Independent Auditor's Review Report on Unaudited Standalone Financial Results for the quarter ended June 30, 2026, of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

To

The Board of Directors,
Panacea Biotec Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Panacea Biotec Limited (the "Company") for the quarter ended June 30, 2026 (hereinafter referred to as "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143 (10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
NOIDA

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under section 133 of Companies Act, 2013 and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Suresh Surana & Associates LLP**
Chartered Accountants
ICAI Reg. No. 121750W/W100010

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
NOIDA

Kapil Kedar
Partner
Membership No. 094902
UDIN: 26094902RSYPZV4787

Dated: August 13, 2026
Place: Noida

Suresh Surana & Associates LLP
Chartered Accountants

Suresh Surana & Associates LLP
2nd Floor, Tower-B
B-37 Sector-1
Noida (NCR) - 201301. (U.P), India
T +91(120) 626 5555
newdelhi@ss-associates.com www.ss-associates.com
LLP Identity No. AAB-7509

Independent Auditor's Review Report on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026, of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

To

The Board of Directors,
Panacea Biotec Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Panacea Biotec Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 (hereinafter referred to as "Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

   The Statement includes the results of the subsidiaries as listed down in Annexure 1.

Suresh Surana & Associates LLP Chartered Accountants NOIDA

Head Office:
8th Floor, Bakhtawar, 229, Nariman Point
Mumbai - 400 021. India. T +91 (22) 6121 4444
emails@ss-associates.com
Offices: Mumbai, Chennai, Kolkata, Bengaluru, Navi Mumbai, Surat, Hyderabad, Ahmedabad, Pune, Gandhidham, Jaipur and Vijayanagar.

4. Based on our review conducted and procedure performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under section 133 of Companies Act, 2013 and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The unaudited consolidated financial result includes the interim financial results and other unaudited financial information of 6 subsidiaries (including 1 foreign subsidiary and 2 step down foreign subsidiaries), whose interim financial results reflect total revenue of Rs. 34 million, total net loss after tax Rs. 14 millions and total comprehensive loss of Rs. 14 millions, for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial results. These interim financial results and other unaudited financial information have not been reviewed by their auditors and have been furnished to us by the management by applying consistent accounting policies. According to the information and explanations given to us by the Management, these interim financial results and other unaudited financial information are not material to the Group.

   Our conclusion on the Statement in respect of the matter stated herein paragraph 5 is not modified with respect to the financial results and other unaudited financial information as certified by the management.

For **Suresh Surana & Associates LLP**
Chartered Accountants
ICAI Reg. No. 121750W/W100010

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
NOIDA

Kapil Kedar
Partner
Membership No. 094902
UDIN: 26094902XYLLIQ5305

Dated: August 13, 2026
Place: Noida

Annexure 1

List of entities included in the Statement

Name of the Holding Company

1) Panacea Biotec Limited

Name of subsidiaries and step-down subsidiaries

1) Panacea Biotec Pharma Limited
2) Panacea Biotec (International) SA
3) Panacea Biotec Germany GmBH (Wholly owned Subsidiary of Panacea Biotec (International) SA)
4) PanEra Biotec Private Limited*
5) Meyten Realtech Private Limited
6) Adveta Power Private Limited*
7) Panacea Biotec Inc (Wholly owned subsidiary of Panacea Biotec Pharma Limited)

*Enterprises over which the Company exercises control – These entities are considered as a subsidiary for the purpose of consolidation as per Ind AS 110.

SURESH SURANA & ASSOCIATES LLP Chartered Accountants NOIDA